



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶ : A61K 35/16, B01D 21/26, C07K 14/75, C12Q 1/56	A1	(11) International Publication Number: WO 99/20288 (43) International Publication Date: 29 April 1999 (29.04.99)
(21) International Application Number: PCT/US98/21626 (22) International Filing Date: 16 October 1998 (16.10.98) (30) Priority Data: 60/062,264 17 October 1997 (17.10.97) US (71) Applicant (for all designated States except US): HARVEST TECHNOLOGIES CORPORATION [US/US]; 77 Accord Park Drive D-7, Norwell, MA 02061 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): BLASETTI, Lou [US/US]; 77 Accord Park Drive D-7, Norwell, MA 02061 (US). (74) Agent: CLARK, Conrad, J.; Dickinson Wright PLLC, Suite 800, 1901 L Street, N.W., Washington, DC 20036 (US).	(81) Designated States: CA, CN, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>	
(54) Title: PRECIPITATION OF GROWTH-FACTOR-ENRICHED FIBRINOGEN CONCENTRATE FROM PLATELET RICH PLASMA (57) Abstract <p>Increased fibrinogen yields are obtained by adding a precipitating agent to plasma having a high platelet concentration, such as platelet rich plasma. The precipitating agent may be any of several known agents, including polyethylene glycol and ammonium sulfate. The platelet rich plasma is obtained in the preferred embodiment by subjecting plasma to "soft spin" centrifugation of about 580G. An automatic, multiple decanting and multiple-speed centrifuge is preferably used to separate anti-coagulated whole blood into the platelet rich plasma component and red blood cells. The proteins, preferably fibrinogen, FXIII, and FVIII, in the platelet rich component are precipitated, and the proteins and platelets are then concentrated by further centrifugation.</p>		

COPY